JPWO2021074790A5 - - Google Patents

Download PDF

Info

Publication number: JPWO2021074790A5
Authority: JP; Japan
Prior art keywords: pain; once; agonist; inflammation; days
Prior art date: 2024-07-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2022522266A

Other languages

English (en)

Japanese (ja)

Other versions

JP2022551730A (ja

Publication date

2024-07-04

2020-10-13 Application filed filed Critical

2020-10-13 Priority claimed from PCT/IB2020/059608 external-priority patent/WO2021074790A1/en

2022-12-13 Publication of JP2022551730A publication Critical patent/JP2022551730A/ja

2024-07-04 Publication of JPWO2021074790A5 publication Critical patent/JPWO2021074790A5/ja

Status Pending legal-status Critical Current

Links

230000036407 pain Effects 0.000 claims description 18
208000002193 Pain Diseases 0.000 claims description 16
QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 15
ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 13
QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 12
229950011318 cannabidiol Drugs 0.000 claims description 12
PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 12
230000004054 inflammatory process Effects 0.000 claims description 12
206010061218 Inflammation Diseases 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 5
206010003246 arthritis Diseases 0.000 claims description 4
150000001875 compounds Chemical class 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 4
230000001225 therapeutic effect Effects 0.000 claims description 4
208000019695 Migraine disease Diseases 0.000 claims description 3
208000004296 neuralgia Diseases 0.000 claims description 3
208000021722 neuropathic pain Diseases 0.000 claims description 3
230000037317 transdermal delivery Effects 0.000 claims description 3
208000030507 AIDS Diseases 0.000 claims description 2
208000001640 Fibromyalgia Diseases 0.000 claims description 2
206010065390 Inflammatory pain Diseases 0.000 claims description 2
208000007101 Muscle Cramp Diseases 0.000 claims description 2
206010033799 Paralysis Diseases 0.000 claims description 2
208000005392 Spasm Diseases 0.000 claims description 2
239000003963 antioxidant agent Substances 0.000 claims description 2
239000004615 ingredient Substances 0.000 claims description 2
201000006417 multiple sclerosis Diseases 0.000 claims description 2
239000011159 matrix material Substances 0.000 claims 10
239000008194 pharmaceutical composition Substances 0.000 claims 9
239000004480 active ingredient Substances 0.000 claims 6
208000029560 autism spectrum disease Diseases 0.000 claims 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
238000000034 method Methods 0.000 claims 3
208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 2
208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 2
206010019705 Hepatic pain Diseases 0.000 claims 2
201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 2
206010038490 Renal pain Diseases 0.000 claims 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
208000006454 hepatitis Diseases 0.000 claims 2
208000018191 liver inflammation Diseases 0.000 claims 2
206010027599 migraine Diseases 0.000 claims 2
201000008383 nephritis Diseases 0.000 claims 2
239000002904 solvent Substances 0.000 claims 2
239000003381 stabilizer Substances 0.000 claims 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
239000004322 Butylated hydroxytoluene Substances 0.000 claims 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
208000001387 Causalgia Diseases 0.000 claims 1
208000000094 Chronic Pain Diseases 0.000 claims 1
208000006561 Cluster Headache Diseases 0.000 claims 1
206010019233 Headaches Diseases 0.000 claims 1
208000008839 Kidney Neoplasms Diseases 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 claims 1
208000001294 Nociceptive Pain Diseases 0.000 claims 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
239000005642 Oleic acid Substances 0.000 claims 1
239000004820 Pressure-sensitive adhesive Substances 0.000 claims 1
206010038389 Renal cancer Diseases 0.000 claims 1
206010040880 Skin irritation Diseases 0.000 claims 1
208000008548 Tension-Type Headache Diseases 0.000 claims 1
238000010521 absorption reaction Methods 0.000 claims 1
208000005298 acute pain Diseases 0.000 claims 1
230000003078 antioxidant effect Effects 0.000 claims 1
229940095259 butylated hydroxytoluene Drugs 0.000 claims 1
235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
201000011510 cancer Diseases 0.000 claims 1
239000003638 chemical reducing agent Substances 0.000 claims 1
208000018912 cluster headache syndrome Diseases 0.000 claims 1
208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 1
239000002270 dispersing agent Substances 0.000 claims 1
239000002552 dosage form Substances 0.000 claims 1
239000003974 emollient agent Substances 0.000 claims 1
239000003349 gelling agent Substances 0.000 claims 1
231100000869 headache Toxicity 0.000 claims 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
201000010982 kidney cancer Diseases 0.000 claims 1
208000017169 kidney disease Diseases 0.000 claims 1
201000007270 liver cancer Diseases 0.000 claims 1
208000019423 liver disease Diseases 0.000 claims 1
208000014018 liver neoplasm Diseases 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
239000007800 oxidant agent Substances 0.000 claims 1
239000003961 penetration enhancing agent Substances 0.000 claims 1
230000036470 plasma concentration Effects 0.000 claims 1
239000004014 plasticizer Substances 0.000 claims 1
229920000642 polymer Polymers 0.000 claims 1
229920001296 polysiloxane Polymers 0.000 claims 1
210000002966 serum Anatomy 0.000 claims 1
235000012239 silicon dioxide Nutrition 0.000 claims 1
239000000377 silicon dioxide Substances 0.000 claims 1
230000036556 skin irritation Effects 0.000 claims 1
231100000475 skin irritation Toxicity 0.000 claims 1
239000004094 surface-active agent Substances 0.000 claims 1
239000000375 suspending agent Substances 0.000 claims 1
230000002459 sustained effect Effects 0.000 claims 1
230000000699 topical effect Effects 0.000 claims 1
239000000556 agonist Substances 0.000 description 49
230000003389 potentiating effect Effects 0.000 description 38
229930003827 cannabinoid Natural products 0.000 description 31
239000003557 cannabinoid Substances 0.000 description 31
230000000202 analgesic effect Effects 0.000 description 28
102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 25
108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 25
102000009135 CB2 Cannabinoid Receptor Human genes 0.000 description 25
108010073376 CB2 Cannabinoid Receptor Proteins 0.000 description 25
102100033868 Cannabinoid receptor 1 Human genes 0.000 description 23
102100036214 Cannabinoid receptor 2 Human genes 0.000 description 19
CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 16
229960004242 dronabinol Drugs 0.000 description 13
CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 10
239000003556 cannabinoid 2 receptor agonist Substances 0.000 description 10
239000003537 cannabinoid receptor agonist Substances 0.000 description 6
229940121376 cannabinoid receptor agonist Drugs 0.000 description 6
230000000694 effects Effects 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
YCHYFHOSGQABSW-RTBURBONSA-N (6ar,10ar)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene-9-carboxylic acid Chemical compound C1C(C(O)=O)=CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 YCHYFHOSGQABSW-RTBURBONSA-N 0.000 description 5
LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 5
239000003554 cannabinoid 1 receptor agonist Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
SZQZAUQREUIIJH-UHFFFAOYSA-N 1h-indol-2-yl(naphthalen-1-yl)methanone Chemical compound C1=CC=C2C(C(C=3NC4=CC=CC=C4C=3)=O)=CC=CC2=C1 SZQZAUQREUIIJH-UHFFFAOYSA-N 0.000 description 4
241000218236 Cannabis Species 0.000 description 4
-1 Hydrogen salt Chemical class 0.000 description 4
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
JDNLPKCAXICMBW-UHFFFAOYSA-N JWH 018 Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)C1=CC=CC2=CC=CC=C12 JDNLPKCAXICMBW-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 4
ZPNWJGPRXXTUNI-UHFFFAOYSA-N 1-(1h-indol-2-yl)-2-phenylethanone Chemical compound C=1C2=CC=CC=C2NC=1C(=O)CC1=CC=CC=C1 ZPNWJGPRXXTUNI-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
102000018208 Cannabinoid Receptor Human genes 0.000 description 3
108050007331 Cannabinoid receptor Proteins 0.000 description 3
201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 3
229940065144 cannabinoids Drugs 0.000 description 3
239000003446 ligand Substances 0.000 description 3
AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
LDTJKFUAZQDSQS-UHFFFAOYSA-N 2-methyl-3-(naphthalen-1-ylmethyl)-1-pentylindole Chemical compound C12=CC=CC=C2N(CCCCC)C(C)=C1CC1=CC=CC2=CC=CC=C12 LDTJKFUAZQDSQS-UHFFFAOYSA-N 0.000 description 2
OTYBPWBZUDBUQS-UHFFFAOYSA-N 3-[(4-methoxynaphthalen-1-yl)methyl]-1-pentylindole Chemical compound CCCCCN1C=C(CC2=CC=C(OC)C3=CC=CC=C23)C2=CC=CC=C12 OTYBPWBZUDBUQS-UHFFFAOYSA-N 0.000 description 2
FSOLXFPDIJJWBM-UHFFFAOYSA-N 3-[(4-methylnaphthalen-1-yl)methyl]-1-pentylindole Chemical compound C12=CC=CC=C2N(CCCCC)C=C1CC1=CC=C(C)C2=CC=CC=C12 FSOLXFPDIJJWBM-UHFFFAOYSA-N 0.000 description 2
ALQFAGFPQCBPED-UHFFFAOYSA-N AM2201 Chemical compound C12=CC=CC=C2N(CCCCCF)C=C1C(=O)C1=CC=CC2=CC=CC=C12 ALQFAGFPQCBPED-UHFFFAOYSA-N 0.000 description 2
VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 2
201000007547 Dravet syndrome Diseases 0.000 description 2
208000004454 Hyperalgesia Diseases 0.000 description 2
LACIUQLUNACUKC-UHFFFAOYSA-N JWH182 Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)C1=CC=C(CC)C2=CC=CC=C12 LACIUQLUNACUKC-UHFFFAOYSA-N 0.000 description 2
QWHSUXWDDKWTOG-UHFFFAOYSA-N Methanone, (4-methoxy-1-naphthalenyl)[1-[2-(4-morpholinyl)ethyl]-1h-indol-3-yl]- Chemical compound C12=CC=CC=C2C(OC)=CC=C1C(=O)C(C1=CC=CC=C11)=CN1CCN1CCOCC1 QWHSUXWDDKWTOG-UHFFFAOYSA-N 0.000 description 2
208000036572 Myoclonic epilepsy Diseases 0.000 description 2
150000001200 N-acyl ethanolamides Chemical class 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
206010028813 Nausea Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 2
150000001447 alkali salts Chemical class 0.000 description 2
230000033115 angiogenesis Effects 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
239000002621 endocannabinoid Substances 0.000 description 2
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
CNTCHEBQQFICNR-UHFFFAOYSA-N jwh-098 Chemical compound C12=CC=CC=C2N(CCCCC)C(C)=C1C(=O)C1=CC=C(OC)C2=CC=CC=C12 CNTCHEBQQFICNR-UHFFFAOYSA-N 0.000 description 2
TYBRSILIYTUTSQ-UHFFFAOYSA-N jwh-175 Chemical compound C12=CC=CC=C2N(CCCCC)C=C1CC1=CC=CC2=CC=CC=C12 TYBRSILIYTUTSQ-UHFFFAOYSA-N 0.000 description 2
YBIPNGRKUAVSBG-UHFFFAOYSA-N jwh-251 Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)CC1=CC=CC=C1C YBIPNGRKUAVSBG-UHFFFAOYSA-N 0.000 description 2
XZVYWLVYUAQEIM-UHFFFAOYSA-N jwh-302 Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)CC1=CC=CC(OC)=C1 XZVYWLVYUAQEIM-UHFFFAOYSA-N 0.000 description 2
239000007788 liquid Substances 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
230000008693 nausea Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 description 2
229960003015 rimonabant Drugs 0.000 description 2
239000000932 sedative agent Substances 0.000 description 2
230000001624 sedative effect Effects 0.000 description 2
239000006208 topical dosage form Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
208000009999 tuberous sclerosis Diseases 0.000 description 2
RQWLYQGWFKBOIY-UHFFFAOYSA-N (1-butyl-2-methylindol-3-yl)-(7-methylnaphthalen-1-yl)methanone Chemical compound C12=CC=CC=C2N(CCCC)C(C)=C1C(=O)C1=CC=CC2=CC=C(C)C=C12 RQWLYQGWFKBOIY-UHFFFAOYSA-N 0.000 description 1
MRZUOBIFOHQHRD-UHFFFAOYSA-N (2-methyl-1-pentylindol-3-yl)-(4-propylnaphthalen-1-yl)methanone Chemical compound C12=CC=CC=C2N(CCCCC)C(C)=C1C(=O)C1=CC=C(CCC)C2=CC=CC=C12 MRZUOBIFOHQHRD-UHFFFAOYSA-N 0.000 description 1
LJSBBBWQTLXQEN-UHFFFAOYSA-N (2-methyl-1-propyl-3-indolyl)-(1-naphthalenyl)methanone Chemical compound C12=CC=CC=C2N(CCC)C(C)=C1C(=O)C1=CC=CC2=CC=CC=C12 LJSBBBWQTLXQEN-UHFFFAOYSA-N 0.000 description 1
VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
GRWSWDKSCZKGSY-UHFFFAOYSA-N (4-bromonaphthalen-1-yl)-(1-pentylindol-3-yl)methanone Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)C1=CC=C(Br)C2=CC=CC=C12 GRWSWDKSCZKGSY-UHFFFAOYSA-N 0.000 description 1
XBWLJRIQVBWALY-UHFFFAOYSA-N (4-ethoxynaphthalen-1-yl)-(1-pentylindol-3-yl)methanone Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)C1=CC=C(OCC)C2=CC=CC=C12 XBWLJRIQVBWALY-UHFFFAOYSA-N 0.000 description 1
JAVDQKMSPNBPCK-UHFFFAOYSA-N (4-ethylnaphthalen-1-yl)-(2-methyl-1-pentylindol-3-yl)methanone Chemical compound C12=CC=CC=C2N(CCCCC)C(C)=C1C(=O)C1=CC=C(CC)C2=CC=CC=C12 JAVDQKMSPNBPCK-UHFFFAOYSA-N 0.000 description 1
QVZOWUCARQBOOX-DOFZRALJSA-N (5z,8z,11z,14z)-n-(2-hydroxyphenyl)icosa-5,8,11,14-tetraenamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NC1=CC=CC=C1O QVZOWUCARQBOOX-DOFZRALJSA-N 0.000 description 1
JCOOBICVPDFZNX-UHFFFAOYSA-N (6-methoxynaphthalen-1-yl)-(1-pentylindol-3-yl)methanone Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)C1=CC=CC2=CC(OC)=CC=C12 JCOOBICVPDFZNX-UHFFFAOYSA-N 0.000 description 1
PUBXDTLETUTKIJ-WOJBJXKFSA-N (6ar,10ar)-1-methoxy-6,6,9-trimethyl-3-(2-methylheptan-2-yl)-6a,7,8,10a-tetrahydrobenzo[c]chromene Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCC)=CC(OC)=C3[C@@H]21 PUBXDTLETUTKIJ-WOJBJXKFSA-N 0.000 description 1
BDJRWUBZMGSKHL-BHIYHBOVSA-N (6ar,10ar)-3-[(3r)-2,3-dimethylpentan-2-yl]-1-methoxy-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromene Chemical compound C1C(C)=CC[C@H]2C(C)(C)OC3=CC(C(C)(C)[C@H](C)CC)=CC(OC)=C3[C@@H]21 BDJRWUBZMGSKHL-BHIYHBOVSA-N 0.000 description 1
NLUGKAUYCBHVKU-UHFFFAOYSA-N (7-ethylnaphthalen-1-yl)-(1-pentylindol-3-yl)methanone Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)C1=CC=CC2=CC=C(CC)C=C12 NLUGKAUYCBHVKU-UHFFFAOYSA-N 0.000 description 1
BVRXLMVNOFBNCJ-UHFFFAOYSA-N 1-(2-methyl-1-pentylindol-3-yl)-2-phenylethanone Chemical compound C12=CC=CC=C2N(CCCCC)C(C)=C1C(=O)CC1=CC=CC=C1 BVRXLMVNOFBNCJ-UHFFFAOYSA-N 0.000 description 1
LFFIIZFINPPEMC-UHFFFAOYSA-N 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole Chemical compound C12=CC=CC=C2N(CCCCCF)C=C1C(=O)C1=CC=CC=C1I LFFIIZFINPPEMC-UHFFFAOYSA-N 0.000 description 1
VCHHHSMPMLNVGS-UHFFFAOYSA-N 1-Butyl-3-(1-naphthoyl)indole Chemical compound C12=CC=CC=C2N(CCCC)C=C1C(=O)C1=CC=CC2=CC=CC=C12 VCHHHSMPMLNVGS-UHFFFAOYSA-N 0.000 description 1
FPESBQVTVSBBSE-OQKWZONESA-N 1-[(e)-(3-pentylinden-1-ylidene)methyl]naphthalene Chemical compound C12=CC=CC=C2C(CCCCC)=C\C1=C/C1=CC=CC2=CC=CC=C12 FPESBQVTVSBBSE-OQKWZONESA-N 0.000 description 1
YOVRGSHRZRJTLZ-HZPDHXFCSA-N 11-nor-9-carboxy-Delta(9)-tetrahydrocannabinol Chemical compound C1=C(C(O)=O)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 YOVRGSHRZRJTLZ-HZPDHXFCSA-N 0.000 description 1
ZWWRREXSUJTKNN-FUHWJXTLSA-N 2-[(1s,3r)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol Chemical compound OC1=CC(C(C)(C)CCCCCC)=CC=C1[C@@H]1C[C@H](O)CCC1 ZWWRREXSUJTKNN-FUHWJXTLSA-N 0.000 description 1
GBWXBGHPYIJYPV-UHFFFAOYSA-N 2-methyl-1-pentylindole Chemical compound C1=CC=C2N(CCCCC)C(C)=CC2=C1 GBWXBGHPYIJYPV-UHFFFAOYSA-N 0.000 description 1
IUTOGLISLDLIBY-UHFFFAOYSA-N 2-methyl-3-[(4-methylnaphthalen-1-yl)methyl]-1-pentylindole Chemical compound C12=CC=CC=C2N(CCCCC)C(C)=C1CC1=CC=C(C)C2=CC=CC=C12 IUTOGLISLDLIBY-UHFFFAOYSA-N 0.000 description 1
SQBCXDRECZTJJW-UHFFFAOYSA-N 4-[2-[3-(naphthalen-1-ylmethyl)indol-1-yl]ethyl]morpholine Chemical compound C1=C(CC=2C3=CC=CC=C3C=CC=2)C2=CC=CC=C2N1CCN1CCOCC1 SQBCXDRECZTJJW-UHFFFAOYSA-N 0.000 description 1
TVLZFNOPMMBZFD-UHFFFAOYSA-N 4-[2-[3-[(4-methylnaphthalen-1-yl)methyl]indol-1-yl]ethyl]morpholine Chemical compound N1(CCOCC1)CCN1C=C(C2=CC=CC=C12)CC1=CC=C(C2=CC=CC=C12)C TVLZFNOPMMBZFD-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical class CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
241000195940 Bryophyta Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 1
229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
102100027297 Fatty acid 2-hydroxylase Human genes 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 description 1
101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
208000035154 Hyperesthesia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
YSBFLLZNALVODA-RBUKOAKNSA-N JWH-133 Chemical compound C1C(C)=CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCC)=CC=C3[C@@H]21 YSBFLLZNALVODA-RBUKOAKNSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000218922 Magnoliophyta Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
244000062730 Melissa officinalis Species 0.000 description 1
235000010654 Melissa officinalis Nutrition 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000023984 PPAR alpha Human genes 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010039897 Sedation Diseases 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102000003563 TRPV Human genes 0.000 description 1
108060008564 TRPV Proteins 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
HQVHOQAKMCMIIM-HXUWFJFHSA-N WIN 55212-2 Chemical compound C([C@@H]1COC=2C=CC=C3C(C(=O)C=4C5=CC=CC=C5C=CC=4)=C(N1C3=2)C)N1CCOCC1 HQVHOQAKMCMIIM-HXUWFJFHSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
WYNZPDDTQGVCLZ-UHFFFAOYSA-N [5-(2-fluorophenyl)-1-pentylpyrrol-3-yl]-naphthalen-1-ylmethanone Chemical compound CCCCCN1C=C(C(=O)C=2C3=CC=CC=C3C=CC=2)C=C1C1=CC=CC=C1F WYNZPDDTQGVCLZ-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
208000029650 alcohol withdrawal Diseases 0.000 description 1
206010053552 allodynia Diseases 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000036592 analgesia Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
229940121369 angiogenesis inhibitor Drugs 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003574 anti-allodynic effect Effects 0.000 description 1
230000003217 anti-cancerogenic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
230000004596 appetite loss Effects 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
239000002585 base Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 1
239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
229960003453 cannabinol Drugs 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000004410 intraocular pressure Effects 0.000 description 1
229940125425 inverse agonist Drugs 0.000 description 1
IBBNKINXTRKICJ-UHFFFAOYSA-N jwh-007 Chemical compound C12=CC=CC=C2N(CCCCC)C(C)=C1C(=O)C1=CC=CC2=CC=CC=C12 IBBNKINXTRKICJ-UHFFFAOYSA-N 0.000 description 1
VPBJQDBKZSHCPC-UHFFFAOYSA-N jwh-030 Chemical compound CCCCCN1C=CC(C(=O)C=2C3=CC=CC=C3C=CC=2)=C1 VPBJQDBKZSHCPC-UHFFFAOYSA-N 0.000 description 1
HSGMJSSWGKDWNA-UHFFFAOYSA-N jwh-048 Chemical compound C12=CC=CC=C2N(CCCCC)C(C)=C1C(=O)C1=CC=CC2=CC=C(C)C=C12 HSGMJSSWGKDWNA-UHFFFAOYSA-N 0.000 description 1
ORTVDISIJXKUAV-FCHUYYIVSA-N jwh-051 Chemical compound C1C(CO)=CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC=C3[C@@H]21 ORTVDISIJXKUAV-FCHUYYIVSA-N 0.000 description 1
JEEFMLVJZKFOFV-FCHUYYIVSA-N jwh-057 Chemical compound C1C(C)=CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC=C3[C@@H]21 JEEFMLVJZKFOFV-FCHUYYIVSA-N 0.000 description 1
AQHPTHKEKSWGPO-UHFFFAOYSA-N jwh-116 Chemical compound C12=CC=CC=C2N(CCCCC)C(CC)=C1C(=O)C1=CC=CC2=CC=CC=C12 AQHPTHKEKSWGPO-UHFFFAOYSA-N 0.000 description 1
DUBUGSKBMMXSOU-UHFFFAOYSA-N jwh-120 Chemical compound C12=CC=CC=C2N(CCC)C=C1C(=O)C1=CC=C(C)C2=CC=CC=C12 DUBUGSKBMMXSOU-UHFFFAOYSA-N 0.000 description 1
HUKJQMKQFWYIHS-UHFFFAOYSA-N jwh-122 Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)C1=CC=C(C)C2=CC=CC=C12 HUKJQMKQFWYIHS-UHFFFAOYSA-N 0.000 description 1
FRMYAMAGHYHNKF-UHFFFAOYSA-N jwh-147 Chemical compound CCCCCCN1C=C(C(=O)C=2C3=CC=CC=C3C=CC=2)C=C1C1=CC=CC=C1 FRMYAMAGHYHNKF-UHFFFAOYSA-N 0.000 description 1
WRIOMNWYCFMMEY-UHFFFAOYSA-N jwh-148 Chemical compound C12=CC=CC=C2N(CCC)C(C)=C1C(=O)C1=CC=C(C)C2=CC=CC=C12 WRIOMNWYCFMMEY-UHFFFAOYSA-N 0.000 description 1
JTJAMXUOXJGSCW-UHFFFAOYSA-N jwh-149 Chemical compound C12=CC=CC=C2N(CCCCC)C(C)=C1C(=O)C1=CC=C(C)C2=CC=CC=C12 JTJAMXUOXJGSCW-UHFFFAOYSA-N 0.000 description 1
VDJUAFPNHZRTNL-WOJBJXKFSA-N jwh-161 Chemical compound C([C@H]12)=C(C)CC[C@H]1C(C)(C)OC1=C2C(O)=C2C3=CC=CC=C3N(CCCCC)C2=C1 VDJUAFPNHZRTNL-WOJBJXKFSA-N 0.000 description 1
IJNSZBAEVYRFCH-UHFFFAOYSA-N jwh-164 Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)C1=CC=CC2=CC=C(OC)C=C12 IJNSZBAEVYRFCH-UHFFFAOYSA-N 0.000 description 1
AMCPOEOUXQWESI-UHFFFAOYSA-N jwh-167 Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)CC1=CC=CC=C1 AMCPOEOUXQWESI-UHFFFAOYSA-N 0.000 description 1
FPESBQVTVSBBSE-UHFFFAOYSA-N jwh-176 Chemical compound C12=CC=CC=C2C(CCCCC)=CC1=CC1=CC=CC2=CC=CC=C12 FPESBQVTVSBBSE-UHFFFAOYSA-N 0.000 description 1
SZWYXJHTNGJPKU-UHFFFAOYSA-N jwh-200 Chemical compound C=1C=CC2=CC=CC=C2C=1C(=O)C(C1=CC=CC=C11)=CN1CCN1CCOCC1 SZWYXJHTNGJPKU-UHFFFAOYSA-N 0.000 description 1
FFLSJIQJQKDDCM-UHFFFAOYSA-N jwh-250 Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)CC1=CC=CC=C1OC FFLSJIQJQKDDCM-UHFFFAOYSA-N 0.000 description 1
QXZYVJRMQVOOEQ-UHFFFAOYSA-N jwh-424 Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)C1=CC=CC2=CC=CC(Br)=C12 QXZYVJRMQVOOEQ-UHFFFAOYSA-N 0.000 description 1
239000000865 liniment Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
235000021266 loss of appetite Nutrition 0.000 description 1
208000019017 loss of appetite Diseases 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
229940099262 marinol Drugs 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
239000011785 micronutrient Substances 0.000 description 1
235000013369 micronutrients Nutrition 0.000 description 1
235000011929 mousse Nutrition 0.000 description 1
239000002623 mu opiate receptor antagonist Substances 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000007908 nanoemulsion Substances 0.000 description 1
239000006070 nanosuspension Substances 0.000 description 1
ACLUUJWYNUJGGO-UHFFFAOYSA-N naphthalen-1-yl(1h-pyrrol-2-yl)methanone Chemical compound C=1C=CC2=CC=CC=C2C=1C(=O)C1=CC=CN1 ACLUUJWYNUJGGO-UHFFFAOYSA-N 0.000 description 1
210000001178 neural stem cell Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
BOWVQLFMWHZBEF-KTKRTIGZSA-N oleoyl ethanolamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)NCCO BOWVQLFMWHZBEF-KTKRTIGZSA-N 0.000 description 1
229940000673 orphan drug Drugs 0.000 description 1
239000002859 orphan drug Substances 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
235000017807 phytochemicals Nutrition 0.000 description 1
229930000223 plant secondary metabolite Natural products 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000001023 pro-angiogenic effect Effects 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
230000036280 sedation Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000035882 stress Effects 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
239000000725 suspension Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
230000001331 thermoregulatory effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

JP2022522266A 2019-10-14 2020-10-13 カンナビジオールの経皮送達 Pending JP2022551730A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201962914662P	2019-10-14	2019-10-14
US62/914,662		2019-10-14
PCT/IB2020/059608 WO2021074790A1 (en)	2019-10-14	2020-10-13	Transdermal delivery of cannabidiol

Publications (2)

Publication Number	Publication Date
JP2022551730A JP2022551730A (ja)	2022-12-13
JPWO2021074790A5 true JPWO2021074790A5 (es)	2024-07-04

Family

ID=75382383

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2022522266A Pending JP2022551730A (ja)	2019-10-14	2020-10-13	カンナビジオールの経皮送達

Country Status (8)

Country	Link
US (1)	US12097293B2 (es)
EP (1)	EP4045024A4 (es)
JP (1)	JP2022551730A (es)
CN (1)	CN114555068A (es)
AU (1)	AU2020366147B2 (es)
CA (1)	CA3155181A1 (es)
MX (1)	MX2022004258A (es)
WO (1)	WO2021074790A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11504327B1 (en)	2019-01-21	2022-11-22	Eric Morrison	Method of preparing nanoparticles by hot-melt extrusion
EP4041209A4 (en)	2019-10-11	2024-01-24	Pike Therapeutics, Inc.	TRANSDERMAL COMPOSITIONS CONTAINING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF SEIZURE DISORDERS
US12016829B2 (en)	2019-10-11	2024-06-25	Pike Therapeutics Inc.	Pharmaceutical composition and method for treating seizure disorders
MX2022004258A (es)	2019-10-14	2022-05-26	Pike Therapeutics Inc	Entrega transdermica de cannabidiol.
US12121617B2 (en)	2019-10-14	2024-10-22	Pike Therapeutics Inc.	Transdermal delivery of cannabidiol
US12268699B2 (en)	2019-10-14	2025-04-08	Pike Therapeutics Inc.	Transdermal delivery of tetrahydrocannabinol
US20220175718A1 (en) *	2020-12-03	2022-06-09	Pike Therapeutics, Inc.	Transdermal pharmaceutical formulations for the treatment of cancer
EP4319730A4 (en) *	2021-04-08	2025-03-12	Pike Therapeutics Inc	PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING EPILEPTIC DISORDERS
JP2024513961A (ja) *	2021-04-12	2024-03-27	パイクセラピューティクスインコーポレイテッド	カンナビジオールの経皮送達
JP2024514362A (ja) *	2021-04-22	2024-04-01	パイクセラピューティクスインコーポレイテッド	慢性疼痛の処置のための経皮医薬製剤
EP4098254A1 (en) *	2021-06-04	2022-12-07	Assistance Publique, Hopitaux De Paris	Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
WO2024069613A1 (en) *	2022-09-30	2024-04-04	Atomix Pharmaceuticals Inc.	Compositions and methods for the treatment of temporomandibular joint disorder

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6245347B1 (en)	1995-07-28	2001-06-12	Zars, Inc.	Methods and apparatus for improved administration of pharmaceutically active compounds
US6113940A (en)	1997-03-03	2000-09-05	Brooke; Lawrence L.	Cannabinoid patch and method for cannabis transdermal delivery
US6328992B1 (en)	1997-03-03	2001-12-11	Lawrence L. Brooke	Cannabinoid patch and method for cannabis transdermal delivery
JP2003504321A (ja)	1999-07-08	2003-02-04	オーランド・ハン	リポソーム被包カンナビノイドの肺送達
US20050042271A1 (en)	1999-11-19	2005-02-24	Xel Herbaceuticals, Inc .	Transdermal delivery system for alkaloids of aconitum species
WO2001064149A1 (en)	2000-02-29	2001-09-07	Jie Zhang	Improved transdermal drug patch
US20020019421A1 (en)	2000-07-05	2002-02-14	Roni Biberman	Compositions and therapy for substance addiction
JP3962684B2 (ja) *	2000-11-06	2007-08-22	サムヤンコーポレイション	改善された水分吸収能および接着性を有する経皮投与剤
US8449908B2 (en)	2000-12-22	2013-05-28	Alltranz, Llc	Transdermal delivery of cannabidiol
US20180042842A1 (en)	2001-02-14	2018-02-15	Gw Pharma Limited	Pharmaceutical formulations
US10004684B2 (en)	2001-02-14	2018-06-26	Gw Pharma Limited	Pharmaceutical formulations
EP2286793A3 (en)	2001-02-14	2014-01-08	GW Pharma Limited	Pharmaceutical formulations comprising cannabidiol
US7025992B2 (en)	2001-02-14	2006-04-11	Gw Pharma Limited	Pharmaceutical formulations
CH695661A5 (de)	2001-03-06	2006-07-31	Forsch Hiscia Ver Fuer Krebsfo	Pharmazeutische Zusammensetzung.
GB2377218A (en)	2001-05-04	2003-01-08	Gw Pharmaceuticals Ltd	Process and apparatus for extraction of active substances and enriched extracts from natural products
FI113340B (fi)	2002-02-20	2004-04-15	Tomi Jaervinen	Uudet luonnon syklodekstriinin kompleksit
DE10226494A1 (de)	2002-06-14	2004-01-08	Lts Lohmann Therapie-Systeme Ag	Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
US10538373B2 (en)	2002-08-14	2020-01-21	Gw Pharma Limited	Pharmaceutical formulation
US6946150B2 (en)	2002-08-14	2005-09-20	Gw Pharma Limited	Pharmaceutical formulation
EP1542657B8 (en)	2002-08-14	2012-03-14	GW Pharma Limited	Cannabinoid liquid formulations for mucosal amdinistration
GB2394894B (en)	2002-11-04	2005-08-31	G W Pharma Ltd	New use for pharmaceutical composition
US20050070596A1 (en)	2003-05-12	2005-03-31	David Baker	Methods for treatment of inflammatory diseases using CT-3 or analogs thereof
EP1559423A1 (en)	2004-02-02	2005-08-03	Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno	Medicinal acidic cannabinoids
IL160420A0 (en)	2004-02-16	2004-07-25	Yissum Res Dev Co	Treating or preventing diabetes with cannabidiol
GB2414933B (en)	2004-06-08	2009-07-15	Gw Pharma Ltd	Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
US7671052B2 (en)	2004-10-05	2010-03-02	Adolor Corporation	Phenyl derivatives and methods of use
WO2006044645A2 (en)	2004-10-13	2006-04-27	Adolor Corporation	Sulfamoyl benzamides and methods of their use
US7968594B2 (en)	2005-04-27	2011-06-28	Gw Pharma Limited	Pharmaceutical compositions for the treatment of pain
US20060263421A1 (en)	2005-05-18	2006-11-23	Abeille Pharmaceuticals Inc	Transdermal Method and Patch for Nausea
TWI366460B (en)	2005-06-16	2012-06-21	Euro Celtique Sa	Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070060638A1 (en)	2005-08-26	2007-03-15	Olmstead Mary C	Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
GB2431105A (en)	2005-10-12	2007-04-18	Gw Pharma Ltd	Cannabinoids for the treatment of pulmonary disorders
GB2432312A (en)	2005-11-01	2007-05-23	Gw Pharma Ltd	Pharmaceutical compositions for the treatment of pain
US7544676B2 (en)	2005-11-10	2009-06-09	Adolor Corporation	Sulfamoyl benzamides and methods of their use
GB2434312B (en)	2006-01-18	2011-06-29	Gw Pharma Ltd	Cannabinoid-containing plant extracts as neuroprotective agents
US8481085B2 (en)	2006-06-15	2013-07-09	Gw Pharma Limited	Pharmaceutical compositions comprising cannabigerol
GB2439393B (en)	2006-06-23	2011-05-11	Gw Pharma Ltd	Cannabinoids for use in the treatment of neuropathic pain
US20100184848A1 (en)	2006-07-14	2010-07-22	William Abraham Wine	Transdermal formulations of synthetic cannabinoids and nano colloidal silica
AU2007281918A1 (en)	2006-08-04	2008-02-14	Insys Therapeutics Inc.	Aqueous dronabinol formulations
WO2008021394A2 (en)	2006-08-15	2008-02-21	Theraquest Biosciences, Llc	Pharmaceutical formulations of cannabinoids and method of use
WO2008024408A2 (en)	2006-08-22	2008-02-28	Theraquest Biosciences, Inc.	Pharmaceutical formulations of cannabinoids for application to the skin and method of use
WO2008024490A2 (en)	2006-08-24	2008-02-28	Theraquest Biosciences, Inc.	Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
EP2083825A4 (en)	2006-09-26	2009-11-04	Addiction Res Inst Inc	HEPATITIS C TREATMENT COMPOSITIONS AND METHODS OF USING HEPATITIS C TREATMENT COMPOSITIONS
WO2008063625A2 (en)	2006-11-20	2008-05-29	Adolor Corporation	Pyridine compounds and methods of their use
GB2448535A (en)	2007-04-19	2008-10-22	Gw Pharma Ltd	New use for cannabinoid-containing plant extracts
GB2450741A (en)	2007-07-05	2009-01-07	Gw Pharma Ltd	Cannabinoid containing plant extracts in the treatment of inflammatory bowel disease
GB2450753B (en)	2007-07-06	2012-07-18	Gw Pharma Ltd	New Pharmaceutical formulation
CA2694325C (en)	2007-07-30	2015-09-22	Alltranz Inc.	Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same
JP2010535774A (ja)	2007-08-06	2010-11-25	インシスセラピューティクスインコーポレイテッド	経口カンナビノイド液体製剤および治療方法
GB2459637B (en)	2008-01-21	2012-06-06	Gw Pharma Ltd	New use for cannabinoids
GB2471987B (en)	2008-06-04	2012-02-22	Gw Pharma Ltd	Anti-tumoural effects of cannabinoid combinations
GB2475183B (en)	2008-06-04	2011-11-23	Gw Pharma Ltd	Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
JP5620907B2 (ja)	2008-06-19	2014-11-05	エルテーエスローマンテラピー−ジステーメアーゲー	カチオン性活性剤の経皮送達のための組成物
US20110097393A1 (en)	2008-06-25	2011-04-28	US WorldMeade, LLC	Skin Patches and Sustained-Release Formulations Comprising Lofexidine for Transdermal and Oral Delivery
MX2011011514A (es) *	2009-04-28	2011-11-18	Alltranz Inc	Formulaciones de canabidiol y metodos para utilizarlas.
US20120202891A1 (en)	2009-04-29	2012-08-09	University Of Kentucky Research Foundation	Cannabinoid-Containing Compositions and Methods for Their Use
LT2473475T (lt)	2009-08-31	2017-08-10	Zynerba Pharmaceuticals, Inc.	Kanabidiolio provaisto panaudojimas vietiniam arba transderminiam įvedimui su mikroadatomis
DK2643018T3 (da)	2010-11-23	2021-01-18	Vitaeris Inc	Anti-il-6-antistoffer til behandling af oral mucositis
JP5073124B2 (ja)	2010-12-07	2012-11-14	祐徳薬品工業株式会社	ノルアドレナリン作動性・特異的セロトニン作動性抗うつ薬含有経皮吸収型貼付製剤
US8642645B2 (en)	2011-05-20	2014-02-04	Brooks Kelly Research, LLC.	Pharmaceutical composition comprising Cannabinoids
WO2013009928A1 (en)	2011-07-11	2013-01-17	Organic Medical Research	Cannabinoid formulations
US20130022687A1 (en)	2011-07-19	2013-01-24	Fitzgerald Jr John James	Topical transdermal method for delivering nutrients through the skin for expedited wound healing
GB2514054A (en)	2011-09-29	2014-11-12	Gw Pharma Ltd	A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB201117956D0 (en)	2011-10-18	2011-11-30	Otsuka Pharma Co Ltd	Phytocannabinoids for use in the treatment of breast cancer
US20140348926A1 (en)	2012-01-19	2014-11-27	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Formulation and method for increasing oral bioavailability of drugs
GB2515312A (en)	2013-06-19	2014-12-24	Gw Pharma Ltd	The use of phytocannabinoids in the treatment of ovarian carcinoma
GB2516814B (en)	2013-06-19	2016-08-31	Otsuka Pharma Co Ltd	Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
US20150057342A1 (en)	2013-08-21	2015-02-26	Cannabics Pharmaceuticals Inc	Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof
WO2015066302A2 (en)	2013-10-30	2015-05-07	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Compositions, methods of use, and methods of treatment
US10555927B2 (en)	2013-11-11	2020-02-11	Ilysm, LLC	Compositions and methods for enhancing sexual pleasure and performance
US10064905B1 (en)	2013-11-11	2018-09-04	Ilysm, LLC	Pharmaceutical preparation
GB2524469A (en)	2014-02-14	2015-09-30	Kind Consumer Ltd	A cannabinoid inhaler and composition therefor
US9918961B2 (en)	2014-02-19	2018-03-20	Kind Consumer Limited	Cannabinoid inhaler and composition therefor
US10653787B2 (en)	2014-03-18	2020-05-19	Izun Pharmaceuticals Corp	Water-based cannabinoid and opioid compositions
US20160022627A2 (en)	2014-04-18	2016-01-28	Mary's Medicinals LLC	Transdermal cannabinoid patch
US20160271252A1 (en)	2014-05-29	2016-09-22	Insys Development Company, Inc.	Stable cannabinoid formulations
US11331279B2 (en)	2014-05-29	2022-05-17	Radius Pharmaceuticals, Inc.	Stable cannabinoid formulations
AU2015266897B2 (en)	2014-05-29	2020-07-30	Fresh Cut Development, Llc	Stable cannabinoid formulations
GB2530001B (en)	2014-06-17	2019-01-16	Gw Pharma Ltd	Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
EP3160451B1 (en)	2014-06-27	2021-04-07	Farm To Farma, Inc.	Buccal and sublingual cannabinoid formulations and method of making the same
GB2527590A (en)	2014-06-27	2015-12-30	Otsuka Pharma Co Ltd	Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
US11298477B2 (en)	2014-06-30	2022-04-12	Syqe Medical Ltd.	Methods, devices and systems for pulmonary delivery of active agents
ES2898173T3 (es)	2014-06-30	2022-03-04	Syqe Medical Ltd	Dispositivos y sistemas para la administración pulmonar de principios activos
US20160000843A1 (en)	2014-07-01	2016-01-07	MJAR Holdings, LLC	High cannabidiol cannabis strains
US20160039591A1 (en)	2014-07-22	2016-02-11	Craig E. Kinzer	Packaging systems, devices, methods, and composition including cannabinoid unit dose forms
EP3217995A1 (en)	2014-08-25	2017-09-20	Janing Holding ApS	Device with compositions for delivery to the lungs, the oral mucosa and the brain
CA2859930A1 (en)	2014-09-22	2016-03-22	Antony Paul Hornby	A cannabis topical from heat treated cocount oil
GB2531282A (en)	2014-10-14	2016-04-20	Gw Pharma Ltd	Use of cannabinoids in the treatment of epilepsy
GB2531281A (en)	2014-10-14	2016-04-20	Gw Pharma Ltd	Use of cannabidiol in the treatment of intractable epilepsy
GB201418713D0 (en)	2014-10-21	2014-12-03	Kymab Ltd	Bindings Proteins
US10660872B2 (en)	2014-11-03	2020-05-26	Ramot At Tel-Aviv University Ltd.	Methods for treatment of cognitive decline
US9375417B2 (en)	2014-12-04	2016-06-28	Mary's Medicinals LLC	Transdermal cannabinoid formulations
US10028904B2 (en)	2014-12-04	2018-07-24	Wisconsin Alumni Research Foundation	Transdermal cannabinoid formulations
US20180289665A1 (en)	2014-12-07	2018-10-11	One World Cannabis Ltd	Use of cannabis to treat migraine
WO2016103254A1 (en)	2014-12-21	2016-06-30	One World Cannabis Ltd	Use of cannabis to treat psoriasis
US20190125779A1 (en)	2014-12-30	2019-05-02	University Of Houston System	Pharmaceutical compositions
HK1247084A1 (zh)	2015-02-02	2018-09-21	APIRx Pharmaceuticals, LLC	大麻素和糖醇複合物，製備和使用的方法
US20160338974A1 (en)	2015-03-02	2016-11-24	Afgin Pharma, Llc	Topical regional neuro affective therapy with cannabinoid combination products
US10383816B2 (en)	2015-03-02	2019-08-20	Afgin Pharma, Llc	Topical regional neuro-affective therapy with cannabinoid combination products
AU2016226267A1 (en)	2015-03-02	2017-09-28	Afgin Pharma, Llc	Topical regional neuro-affective therapy with cannabinoids
US20180036303A1 (en)	2015-03-10	2018-02-08	Eleusis Benefit Corporation, Pbc	Lsd for the treatment of alzheimer's disease
AU2016231788A1 (en)	2015-03-19	2017-10-12	One World Cannabis Ltd	Preparations of cannabis emulsions and methods thereof
US9962340B2 (en)	2015-06-09	2018-05-08	Life Tech Global, Llc	Device and method for the transdermal delivery of cannabidiol
GB2539472A (en)	2015-06-17	2016-12-21	Gw Res Ltd	Use of cannabinoids in the treatment of epilepsy
PT3324754T (pt)	2015-07-22	2022-11-30	Phytopharma Int Ltd	Composições ingeríveis por abelhas, métodos de utilização das mesmas para produzir mel e mel produzido desse modo
US9827282B2 (en)	2015-07-24	2017-11-28	Bao Tran	Medication dispensing system
GB2541191A (en)	2015-08-10	2017-02-15	Gw Pharma Ltd	Use of cannabinoids in the treatment of epilepsy
CA2995418A1 (en)	2015-08-11	2017-02-16	KannaInnovations LLC	Topical compositions comprising hydroxy acids and cannabinoids for skin care
US10272125B2 (en)	2015-09-14	2019-04-30	Life Tech Global, Llc	Transdermal delivery of cannabidiol with other active moieties including cannabinoids
US20180344676A1 (en)	2015-09-30	2018-12-06	George Edward Hoag	Topical analgesic pain relief formulations, manufacture and methods of use thereof
US10695287B2 (en)	2015-11-17	2020-06-30	Cersci Therapeutics, Inc.	AMPK agonist topical medication for the treatment of certain specific medical conditions, methods of use thereof and wound dressing employing the same
US20170202895A1 (en)	2016-01-18	2017-07-20	Kevin Anthony Hugh	Cannabis Pellets
US10338355B2 (en)	2016-02-05	2019-07-02	Largan Precision Co., Ltd.	Lens assembly
IL307857A (en)	2016-03-16	2023-12-01	Buzzelet Development And Technologies Ltd	Terpene-enriched cannabinoid composition
CN109069459A (zh)	2016-04-12	2018-12-21	哈比制药私人有限公司	脂质体制剂和治疗方法
LT6486B (lt)	2016-04-13	2018-01-10	UAB "SatiMed"	Aliejinio gelio kompozicija su aktyviausiais junginiais iš c. sativa ir m. arvensis ir jos pateikimo sistema, skirta giliųjų audinių uždegimo ir skausmo mažinimui
EP3445179A4 (en)	2016-04-19	2020-07-22	Canna-B Cure Ltd	ENZYMATICALLY TREATED THERAPEUTIC COMPOSITION ENRICHED IN CANNABIS
AU2017252575B2 (en)	2016-04-22	2021-11-18	Spoke Sciences, Inc.	Fast-acting plant-based medicinal compounds and nutritional supplements
GB2551985B (en)	2016-07-01	2019-01-30	Gw Res Ltd	Novel formulation
GB2551987A (en)	2016-07-01	2018-01-10	Gw Res Ltd	Oral cannabinoid formulations
SG11201811209QA (en)	2016-07-11	2019-01-30	Intec Pharma Ltd	Oral gastroretentive formulations and uses thereof
IL246790A0 (en)	2016-07-14	2016-09-29	Friedman Doron	Self-dissolving compounds of cannabinoids
US20180049994A1 (en)	2016-08-16	2018-02-22	Afgin Pharma, Llc	Topical regional neuro-affective therapy with caryophyllene
GB2553139A (en)	2016-08-25	2018-02-28	Gw Res Ltd	Use of cannabinoids in the treatment of multiple myeloma
US10869842B1 (en)	2016-09-07	2020-12-22	David P Summers	Transdermal delivery of pharmaceutical agents
JP7378781B2 (ja)	2016-09-07	2023-11-14	グリアエルエルシー	脳神経の薬理学的な経皮活性化による神経変性障害に関連する症状の治療
US20200163931A1 (en)	2016-10-12	2020-05-28	Columbia Care Llc	Oral composition of extracted cannabinoids and methods of use thereof
WO2018083697A1 (en)	2016-11-02	2018-05-11	To Pharmaceuticals Llc	Combination therapy of cbd and copaxone
US20190321426A1 (en)	2016-11-02	2019-10-24	Tikun Olam Ltd	Combination therapies with cannabis plant extract
CA3081755A1 (en)	2016-11-07	2018-05-11	Avidas Pharmaceuticals Llc	Therapeutic cannabinoid formulations and methods for their use
EA201892396A1 (ru)	2016-12-02	2019-04-30	Ресептор Лайф Сайенсиз, Инк.	Быстродействующие растительные лекарственные соединения и биологически активные добавки
ES3021876T3 (en)	2016-12-06	2025-05-27	Topical Innovations B V	Topical pharmaceutical composition containing phenytoin and a (co -)an algesic for the treatment of chronic pain
EP3558281A4 (en)	2016-12-15	2020-07-08	Sharon Anavi-Goffer	TREATMENT OF MENTAL DISORDERS, MOVEMENT AND BEHAVIOR
US20180311180A1 (en)	2016-12-29	2018-11-01	International Bioceutical Co. LLC	Modular Transdermal Delivery Systems for the Treatment of Pain and Inflammation
US20180311181A1 (en)	2016-12-29	2018-11-01	International Bioceutical Co. LLC	Modular Transdermal Delivery Systems for the Treatment of Insomnia and Anxiety
JP2020518325A (ja)	2016-12-29	2020-06-25	ピュアレイシオスホールディングス，インコーポレイテッド	モジュール式経皮送達システムならびに製造および使用の関連する方法
NL2018190B1 (en)	2017-01-18	2018-07-26	Procare Beheer B V	Psilocybin or psilocin in combination with cannabinoid
US10675264B2 (en)	2017-02-07	2020-06-09	Elevate Technologies Llc	Terpene-based compositions, methods of preparations and uses thereof
GB2559774B (en)	2017-02-17	2021-09-29	Gw Res Ltd	Oral cannabinoid formulations
GB2560019A (en)	2017-02-27	2018-08-29	Gw Res Ltd	Use of cannabinoids in the treatment of leukaemia
EP3630067A4 (en)	2017-05-26	2021-08-11	Altum Pharmaceuticals Inc.	BIPHASIC CANNABINOID ADMINISTRATION
US10945967B2 (en)	2017-05-30	2021-03-16	Jae Wang. Song	Formulations of a transdermal patch for pain management
AU2018275687A1 (en)	2017-05-31	2020-01-02	Phytecs, Inc.	Pharmaceutical compositions comprising cannabidiol and beta-caryophyllene and methods for their use
WO2019002926A1 (en)	2017-06-27	2019-01-03	Enviro BioMedical Laboratories Inc.	MIXTURE-TYPE CANNABIS COMPOUNDS AND PROCESSES FOR PREPARING THE SAME
CA3068383A1 (en)	2017-06-28	2019-01-03	Buzzelet Development And Technologies Ltd.	Terpene-enriched cannabinoid product for women health
CA3013573A1 (en)	2017-08-08	2019-02-08	Steven Bermudez	Method for reduction, suppression, or elimination of anxiety or marijuana/cannabis effects and related marijuana/cannabis product by process
EP3664796A4 (en)	2017-08-13	2021-05-12	Buzzelet Development And Technologies Ltd	TERPENE-ENRICHED CANNABINOID COMPOSITION AND TREATMENT PROCESS
IL301622A (en)	2017-08-14	2023-05-01	Zynerba Pharmaceuticals Inc	Methods of treatment of osteoarthritis with transdermal cannabidiol gel
WO2019046850A1 (en)	2017-09-02	2019-03-07	Scientific Holdings, Llc	MODULATORS OF TETRAHYDROCANNABINOL
CN109498606A (zh) *	2017-09-15	2019-03-22	汉义生物科技（北京）有限公司	一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
JOP20200045A1 (ar)	2017-09-19	2020-02-27	Zynerba Pharmaceuticals Inc	كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين
EP3684353A4 (en)	2017-09-22	2021-06-23	Inmed Pharmaceuticals Inc.	TOPICAL FORMULATIONS OF CANNABINOIDS AND THEIR USE IN THE TREATMENT OF PAIN
KR102786277B1 (ko)	2017-09-28	2025-03-26	하모니 바이오사이언시즈 매니지먼트, 아이엔씨.	칸나비디올을 이용한 취약 x 증후군의 치료
GB201715919D0 (en)	2017-09-29	2017-11-15	Gw Res Ltd	use of cannabinoids in the treatment of epilepsy
US20210186860A1 (en)	2017-10-17	2021-06-24	Life Tech Global, Llc	Improved Delivery Systems for Moieties Including CBD Enhanced Combinations, Formulations and Chimeras
US10307392B2 (en)	2017-10-21	2019-06-04	Alexander Kariman	Compound and method for treatment of diseases and disorders
EP3709984A4 (en)	2017-11-15	2021-08-11	The Regents of the University of California	TREATMENT OF AN OPIOID USE DISORDER, OPIOID WITHDRAWAL SYMPTOMS AND CHRONIC PAIN
WO2019130215A1 (en)	2017-12-27	2019-07-04	To Pharmaceuticals Llc	Cannabis compositions for the treatment of inflammatory skin disorders
US10722545B2 (en)	2018-01-01	2020-07-28	Alexander Kariman	Compound and method for treatment of movement disorders
GB2572126B (en)	2018-01-03	2021-01-13	Gw Res Ltd	Pharmaceutical
CA3088312A1 (en)	2018-01-12	2019-07-18	Nutrae, LLC	Encapsulated cannabinoid formulations for transdermal delivery
US11759473B2 (en)	2018-02-16	2023-09-19	American Nano, LLC	Topical compositions incorporating silica fibers
BR112020017023A2 (pt)	2018-02-23	2021-03-02	Nicola Michael Spirtos	terapêutica à base de cannabis e método de uso
US20210030777A1 (en)	2018-04-04	2021-02-04	Vinsan Therapeutics Inc.	Topical formuations and instillates, kits, and methods for treating integumentary wounds, and uses thereof
WO2019198056A1 (en)	2018-04-14	2019-10-17	Buzzelet Development And Technologies Ltd	Terpene-enriched cannabinoid composition for treating conditions and/ or symptoms associated with a stressful event
WO2019210287A1 (en)	2018-04-27	2019-10-31	Life Tech Global, Llc	New medical devices, delivery vehicles and manufacturing thereof
GB201806953D0 (en)	2018-04-27	2018-06-13	Gw Res Ltd	Cannabidiol Preparations
US20190328884A1 (en)	2018-04-30	2019-10-31	Chemic Laboratories, Inc.	Compositions and methods of their use
WO2019224824A1 (en)	2018-05-24	2019-11-28	To Pharmaceuticals Llc	Cannabis-based compositions for the treatment of autistic spectrum disorders
US10864189B2 (en)	2018-06-29	2020-12-15	Jenna Borok	Topical compositions comprising polyolprepolymers, stem cell, and cannabinoids for skin care
GB201811834D0 (en)	2018-07-19	2018-09-05	Medherant Ltd	Patch
GB201811833D0 (en)	2018-07-19	2018-09-05	Medherant Ltd	Patch
US20200054887A1 (en)	2018-08-15	2020-02-20	Bruce H. Levin	Topical Therapeutics
US10695301B2 (en)	2018-09-04	2020-06-30	Babak Ghalili	Veterinary cannabinoid and menthol compositions and methods
CA3060926A1 (en)	2018-09-06	2020-03-06	NuVessl, Inc.	Method of using cannabinoids encapsulated in phospholipid carriers for transmucosal and transdermal administration
IL261774B (en)	2018-09-13	2020-04-30	Unv Medicine Ltd	Compositions for treating dermatological conditions
US11357958B2 (en)	2018-10-25	2022-06-14	Medtronic Vascular, Inc.	Devices and techniques for cardiovascular intervention
WO2020115751A1 (en)	2018-12-06	2020-06-11	To Pharmaceuticals Llc	Cannabis-based compositions for the treatment of alzheimer's disease and dementia
EP3893864A4 (en)	2018-12-11	2022-12-07	The Regents Of The University Of Michigan	CO-CRYSTALS, THEIR PROCESS AND FORMATION APPARATUS
KR20210104084A (ko)	2018-12-14	2021-08-24	지네르바 파마슈티컬스, 인코포레이티드	칸나비디올을 사용하는 22q11.2 결실 증후군의 치료
WO2020136593A1 (en)	2018-12-27	2020-07-02	Buzzelet Development And Technologies Ltd.	Herbal preparation-enriched cannabinoid composition and method of treatment
AU2019413789B2 (en)	2018-12-29	2025-05-29	Buzzelet Development And Technologies Ltd.	Isolated or synthetic cannabinoid compositions with selected terpene blend and methods of use thereof
WO2020142692A1 (en)	2019-01-04	2020-07-09	Columbia Care Llc	Topical formulations having cannabinoid
GB2580653A (en)	2019-01-21	2020-07-29	Gw Res Ltd	Use of cannabinoids in the treatment of comorbidities associated with epilepsy
AU2020215164B2 (en)	2019-01-29	2025-04-03	Buzzelet Development And Technologies Ltd.	Terpene-enriched cannabinoid composition and method of treatment for treating conditions and/or symptoms associated with autism spectrum disorder
MX2021009037A (es)	2019-01-30	2021-10-13	Diamond Therapeutics Inc	Composiciones y metodos para el manejo de trastornos.
US20210015740A1 (en)	2019-03-04	2021-01-21	Michael Harvey Greenspan	Topical cannabinoid compositions, delivery systems, and uses for pain relief
CA3129535A1 (en)	2019-03-07	2020-09-10	Oludare ODUMOSU	Formulations for treating cluster symptoms associated with autism spectrum disorder
WO2020183350A1 (en)	2019-03-12	2020-09-17	Radient Technologies Innovations Inc.	Transdermal patch kit with transdermal dosage units
AU2020245520B2 (en)	2019-03-26	2024-12-19	Winsantor, Inc.	Topical formulations for treatment of peripheral neuropathies
WO2020198883A1 (en)	2019-04-03	2020-10-08	Stratemeyer Trinczek Ely Nigel	Transdermal medicament
US20200330379A1 (en)	2019-04-17	2020-10-22	Navinta NV, Inc.	Non-oral cannabinoid formulation and method of treatment
WO2020220092A1 (en)	2019-05-01	2020-11-05	Cannadol Pharmaceuticals	Compositions and methods for pain and anxiety relief
CA3138630A1 (en)	2019-05-02	2020-11-05	Betterlife Pharma Inc.	Cannabinoid stock transdermal formulations
US20200345685A1 (en)	2019-05-02	2020-11-05	Christopher Ayo Otiko	Topical application of medical cannabis
US20200345653A1 (en)	2019-05-02	2020-11-05	Kenda Hansen	Transdermal Composition
US20200352849A1 (en)	2019-05-07	2020-11-12	Adam M. Rotunda	Topical Skin Formulations and Wound Care Products with Integrated CBD Delivery Mechanisms for Skin Rejuvenation, Wound Care and Healing, Pain and Itch Relief, and Scar Prevention and Treatment
WO2020243352A1 (en)	2019-05-28	2020-12-03	Tech Swerve Llc	Penetrating topical pain relief compositions and methods of use
US10842758B1 (en)	2019-06-18	2020-11-24	Ampersand Biopharmaceuticals, Inc.	Transdermal penetrant formulations containing cannabidiol
US10588871B1 (en)	2019-06-28	2020-03-17	Nexzol Pharma, Inc.	Transdermal formulation for the treatment of pain and/or inflammation
JP7597780B2 (ja)	2019-07-02	2024-12-10	ポートランド・テクノロジー・ホールディングス・エルエルシー	動物における疼痛、癌、およびてんかんの治療のための大麻抽出物
WO2021003467A1 (en)	2019-07-04	2021-01-07	Sw Holdings, Inc.	Metered dosing compositions and methods of use of psychedelic compounds
AU2020325925B2 (en)	2019-08-05	2025-05-29	Cs Medica A/S	Topical formulations comprising cannabidiol, method of preparing the composition and use thereof
WO2021050429A1 (en)	2019-09-10	2021-03-18	Pureform Global, Inc.	Topical composition for treatment of pain
CN114401713A (zh)	2019-09-17	2022-04-26	Zyne制药公司	在发育性和癫痫性脑病中的行为损伤的治疗
US11951079B2 (en)	2019-10-03	2024-04-09	Kongkrit Chaiyasate	Topical cannabidiol composition
MX2022004258A (es)	2019-10-14	2022-05-26	Pike Therapeutics Inc	Entrega transdermica de cannabidiol.
US11318093B2 (en)	2019-11-08	2022-05-03	Pac-Dent, Inc.	Dental topical anesthetic gel
US20210145764A1 (en)	2019-11-15	2021-05-20	Brigham Young University	Compositions of cannabidiol (cbd), and/or polyphenols, and methods for the prevention and/or treatment of skin, muscle, nerve and inflammatory disorders, and biological factors and functions in mammals
US20220409601A1 (en)	2019-11-20	2022-12-29	Canole Llc	Combination cannabinoid-nad+ precursor formulation for treatment of inflammation and methods related thereto
US20210244680A1 (en)	2020-02-10	2021-08-12	Ghassan S. Kassab	Wearable liposomal cannabidiol transdermal patch
GB2608314A (en)	2020-02-11	2022-12-28	Babak Ghalili	Cannabinoid and menthol transdermal delivery systems and methods
GB202002754D0 (en)	2020-02-27	2020-04-15	Gw Res Ltd	Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
WO2021177937A1 (en)	2020-03-02	2021-09-10	Babak Ghalili	Cannabinoid and menthol compositions and methods
WO2021177940A1 (en)	2020-03-03	2021-09-10	Babak Ghalili	Cannabinoid and menthol gel compositions, patches and methods
AU2021259495A1 (en)	2020-04-20	2022-10-27	Pike Therapeutics, Inc.	Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain
EP4210714A4 (en)	2020-05-19	2025-01-29	Mig Usa Llc	TOPICAL COMPOSITIONS AND METHODS OF TREATMENT OF PAIN
CN116075296A (zh)	2020-07-01	2023-05-05	长矛治疗股份有限公司	用于治疗多发性硬化症的透皮药物制剂
MX2023000314A (es)	2020-08-17	2023-02-22	Pike Therapeutics Inc	Formulaciones farmaceuticas transdermicas de cannabinoides.
US20220175718A1 (en)	2020-12-03	2022-06-09	Pike Therapeutics, Inc.	Transdermal pharmaceutical formulations for the treatment of cancer

2020
- 2020-10-13 MX MX2022004258A patent/MX2022004258A/es unknown
- 2020-10-13 EP EP20876354.0A patent/EP4045024A4/en active Pending
- 2020-10-13 CA CA3155181A patent/CA3155181A1/en active Pending
- 2020-10-13 US US17/069,181 patent/US12097293B2/en active Active
- 2020-10-13 CN CN202080071854.2A patent/CN114555068A/zh active Pending
- 2020-10-13 JP JP2022522266A patent/JP2022551730A/ja active Pending
- 2020-10-13 WO PCT/IB2020/059608 patent/WO2021074790A1/en unknown
- 2020-10-13 AU AU2020366147A patent/AU2020366147B2/en active Active

Publication	Publication Date	Title
CN115916184A (zh)	2023-04-04	包含大麻二酚和/或四氢大麻酚的治疗慢性疼痛的透皮和/或局部药物制剂
JP2021054836A (ja)	2021-04-08	大麻組成物
JP2022084953A (ja)	2022-06-07	表皮水疱症及び関連する結合組織疾患の治療におけるカンナビノイドの局所製剤の使用
JP2022551730A (ja)	2022-12-13	カンナビジオールの経皮送達
EP2665481B1 (en)	2016-03-30	Methods and compositions for treating metabolic syndrome
CN115884761A (zh)	2023-03-31	大麻素的透皮药物制剂
JPWO2021074790A5 (es)	2024-07-04
US20040156922A1 (en)	2004-08-12	Cancer treatment composition and method using natural plant essential oils with signal transduction modulators
CN116075296A (zh)	2023-05-05	用于治疗多发性硬化症的透皮药物制剂
US20230372275A1 (en)	2023-11-23	Compositions and Methods of Treating or Preventing Fibrotic Lung Diseases
US11318093B2 (en)	2022-05-03	Dental topical anesthetic gel
US10045994B2 (en)	2018-08-14	Agents for treating multiple myeloma
US10966946B2 (en)	2021-04-06	Compounded compositions and methods for treating pain
AU2019465548A1 (en)	2022-03-03	Stable medicinal cannabidiol compositions
BR112020027070A2 (pt)	2021-03-30	Composição e método para poupar opióides
WO2021245672A1 (en)	2021-12-09	Cannabigerolic acid (cbga) derivatives and uses thereof
CA2660939A1 (en)	2008-03-06	Pharmaceutical compositions for the treatment of fungal infections
EP4161900A1 (en)	2023-04-12	Cannabidiolic acid (cbda) derivatives and uses thereof
CA3104739A1 (en)	2020-01-09	Cannabinoid composition and method for treating ptsd and/or anxiety
US20240398750A1 (en)	2024-12-05	Methods of treating or reducing symptoms of anxiety, depression, attention deficiency (ADD), attention deficient hyperactivity (ADHD), obsessive compulsive (OCD), Bipolar disorder, and related disorders/conditions via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and other allosteric modulators.
WO2003011280A1 (en)	2003-02-13	Use of vitamin e succinate and antiandrogen combination
CN117545478A (zh)	2024-02-09	用于治疗慢性疼痛的透皮药物制剂
HK1190936B (en)	2017-06-09	Methods and compositions for treating metabolic syndrome
AU2011221426A1 (en)	2011-09-29	Pharmaceutical compositions for the treatment of fungal infections
AU2002322740A1 (en)	2003-02-17	Use of vitamin succinate and antiandrogen combination